Trial Profile
Phase 2 trial of CXD-201 in the patients with Colorectal-cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs CXD-201 (Primary) ; Capecitabine; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
- 27 Sep 2018 New trial record